Beta-thalassemia major

This trial tests a gene therapy called YOLT-204 in people aged 14 to 35 with sickle cell disease or transfusion-dependent thalassemia. The goal is to see if a single intravenous dose can safely boost fetal hemoglobin levels, potentially reducing or eliminating the need for blood …

This phase 2 trial tests a one-time gene therapy called HGI-001 in people with transfusion-dependent β-thalassemia, a severe blood disorder that requires regular blood transfusions. The therapy takes the patient's own blood stem cells, modifies them outside the body to produce he…

This study tests a single dose of CS-101, a gene therapy, in 20 people aged 12-35 with β-thalassemia major, a severe blood disorder requiring regular transfusions. The goal is to see if it is safe and can help patients produce enough healthy red blood cells to stop needing transf…

This early-phase trial will test a single dose of a new drug called YOLT-204 in 18 children and teens with transfusion-dependent β-thalassemia or sickle cell disease. The goal is to see if it is safe and can raise fetal hemoglobin levels enough to reduce the need for blood transf…

This study tests whether motivational interviewing, a type of counseling, can help adults with beta-thalassemia major follow their iron chelation therapy more consistently. Forty-five participants in Oman will receive three one-on-one sessions with a nurse over six to eight weeks…

This study measures the clinical, economic, and psychosocial burden of thalassemia in children and adolescents in Sohag, Egypt. Researchers will track hospital visits, blood transfusions, and complications, and estimate direct medical costs plus indirect costs like missed school …

This study will test if a special oral health education program can improve the oral hygiene and quality of life of 45 children aged 8-10 with β-thalassemia major. The program teaches proper brushing and dental care. Researchers will measure changes in oral cleanliness and how ch…

This study will measure levels of a small molecule called microRNA-155 in 100 people who need regular blood transfusions, mostly due to beta thalassemia. The goal is to see if higher levels of this molecule are linked to the formation of harmful antibodies against donated blood. …

This study looks at children with beta-thalassemia major, a genetic blood disorder requiring lifelong transfusions. Researchers will measure growth and check for risk factors like iron overload that may stunt development. No new treatment is given—just careful observation of 85 c…

This study looks at how thalassemia patients in Greece feel day-to-day while taking a standard iron-removing medicine called deferasirox. Researchers will survey 150 adults to measure their physical and mental well-being. The goal is to understand real-world quality of life, not …

This study will measure certain hormones in 80 boys aged 10 to 18 who have transfusion-dependent beta thalassemia. The goal is to see how iron buildup from repeated blood transfusions affects the glands that control puberty and fertility. By checking levels of inhibin B, INSL3, a…

This study looks at body composition—fat, muscle, and bone mass—in children aged 5 to 18 with beta thalassemia major who receive regular blood transfusions. Researchers will use a simple test to measure these body components and see how they relate to transfusion frequency, iron …